The results of the ECOG-ACRIN E2100 trial had significant implications for clinical practice. The study provided evidence supporting the use of bevacizumab in combination with paclitaxel for treating metastatic breast cancer, leading to its approval by regulatory agencies. However, the lack of improvement in overall survival and the risk of adverse effects necessitated careful patient selection and monitoring.
